Spectrum, Zentaris cancer deal

SPPI acquired exclusive development and commercialization rights from Zentaris (Frankfurt, Germany) to develop and commercialize D-63153, a fourth-generation luteinizing hormone releasing hormone (LHRH) antagonist for all indications. The rights cover North America and India. D-63153 is in Phase II testing in Europe for prostate cancer. Zentaris will receive an upfront payment in cash and stock, and is eligible for milestones and royalties. Also, the companies will share revenues from a potential development and marketing partner in Japan. AEZ expects to seek a Japan-based partner for D-63153 next year. ...